To determine the activity and safety of 177 Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer (mCRPC) commencing enzalutamide, who are at high risk of early progression; and to identify potential prognostic and predictive biomarkers from imaging, blood, and tissue.

X